| Nov 14 |
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
|
| Nov 12 |
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
|
| Nov 7 |
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
|
| Nov 7 |
Q3 2024 Pacira Biosciences Inc Earnings Call
|
| Nov 7 |
Pacira BioSciences Non-GAAP EPS of $0.79 beats by $0.09, revenue of $168.6M misses by $9.43M
|
| Nov 7 |
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...
|
| Nov 7 |
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Pacira: Q3 Earnings Snapshot
|
| Nov 6 |
Pacira BioSciences Reports Third Quarter 2024 Financial Results
|
| Nov 5 |
Pacira BioSciences Q3 2024 Earnings Preview
|
